Dr. Rotow on Results of a Phase 1/2 Trial With Osimertinib/Gefitinib in EGFR-Mutant NSCLC
June 3rd 2020
Julia K. Rotow, MD, discusses the results of an ongoing phase 1/2 trial evaluating the safety and efficacy of osimertinib in combination with gefitinib as a first-line treatment for patients with stage IV EGFR-mutant non–small cell lung cancer.